Medtronic’s Liberant Thrombectomy System Used in First Commercial Case

December 10, 2025—Medtronic announced the first commercial use of the Liberant thrombectomy system, which is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems.

The first procedure using the Liberant thrombectomy system was performed on November 21 by vascular surgeon Ajit Rao, MD, at The Mount Sinai Hospital in New York.

“The Liberant thrombectomy system is an effective new tool that performs well even in complex cases, maneuvering through challenging anatomy with ease and limiting blood loss through an intelligent algorithm,” commented Dr. Rao in Medtronic’s press release. “We’re able to remove clot burden with greater precision and, for patients, this means a procedure designed to be more efficient and aimed at helping them restore circulation and mobility as safely and effectively as possible.”

According to Medtronic, Liberant expands the company’s portfolio of treatment options for peripheral arterial and venous diseases to include mechanical aspiration thrombectomy.

The Liberant platform is available in 6-F, 8-F (short and long lengths), and 12-F sizes, providing flexibility to treat arterial, venous and arteriovenous vessels. Smaller and larger sizes are in development, with a 5-F rapid exchange catheter expected in early 2026, noted the company.

Medtronic stated that the Liberant platform is compatible with Contego Medical’s Excipio thrombectomy devices—which are rapid exchange catheters with a mechanical basket—used with controlled aspiration for procedural efficiency. Both Liberant and Excipio now have FDA clearance and are available in the United States.

John Laird, MD, Chief Medical Officer, Peripheral Vascular Health, stated, “Liberant is designed to provide precision catheter deliverability while minimizing blood loss during clot removal—two key challenges often faced in thrombectomy procedures. Additionally, Liberant’s compatibility with Excipio devices gives physicians the ability to combine aspiration and clot disruption technologies in particularly challenging cases.”

In January 2025, Medtronic announced it had entered into an exclusive United States distribution agreement with Contego Medical for its portfolio of commercially available revascularization products to treat carotid and peripheral vascular disease, including the Excipio devices. The agreement includes an increased investment in Contego and an option to acquire the company, advised Medtronic.